Calpain has been implicated in excitotoxic neurodegeneration, but its mechanism of action particularly in adult brains remains unclear. We generated mutant mice lacking or overexpressing calpastatin, the only solely calpain-specific inhibitor ever identified or synthesized. Modulation of calpastatin expression caused no defect in the mice under normal conditions, indicating that calpastatin functions as a negative regulator of calpain only under pathological conditions. Kainateevoked excitotoxicity in hippocampus resulted in proteolytic activation of a proapoptotic Bcl-2 subfamily member (Bid), nuclear translocation of mitochondriaderived DNA fragmentation factors (apoptosis-inducing factor and endonuclease G), DNA fragmentation, and nuclear condensation in pyramidal neurons. These apoptotic responses were significantly augmented by calpastatin deficiency. Consistently calpastatin overexpression suppressed them. No evidence of caspase-3 activation was detected. Our results demonstrated that calpain mediates excitotoxic signals through mobilization of proapoptotic factors in a caspase-independent manner. These mutant mice will serve as useful tools for investigating calpain involvement in various diseases.
The phenomenon of excitotoxicity is related to the key pathological processes that are involved not only in acute neuronal cell death evoked by surgical insults such as ischemia and spinal cord injury but also in chronic neurodegeneration that arises in neurological disorders such as Alzheimer disease (1) (2) (3) (4) . Recent clinical evidence for the role of excitotoxicity in the pathogenesis of Alzheimer disease was highlighted by the fact that memantine, a glutamate receptor blocker, alleviates the cognitive defects of Alzheimer patients (5) . Elucidation of the mechanism of excitotoxic neuronal degeneration will therefore contribute to development of strategies for the treatment of both acute and chronic neuronal disorders. Several pieces of experimental evidence (see below) led us to focus our attention in the present study on the role of calpain, a calcium-activated neutral protease, in excitotoxic neuronal death. Because excitotoxicity primarily involves an unphysiological elevation of intraneuronal calcium concentrations, the selective limited proteolysis of intracellular proteins by calpain activated in this way could be responsible for irreversibly modulating substrate functions (6) . This effect could be more damaging than other reversible calcium-dependent processes such as phosphorylation and dephosphorylation.
The involvement of calpain in neuronal cell death has been implicated in various neuropathological circumstances including ischemia, spinal cord injury, multiple sclerosis, Alzheimer disease, Parkinson's disease, and polyglutamine diseases (7) (8) (9) (10) (11) (12) (13) . For example, exposure of gerbil forebrain to short term ischemia followed by reperfusion induces calpain activation in the hippocampus in a spatiotemporal manner, resulting in delayed neuronal death in the CA1 sector of hippocampus (14) . Genetic experiments using Caenorhabditis elegans also provided firm evidence for the involvement of calpain in neuronal death (15) . Although a number of calpain substrates including cytoskeletal proteins, kinases, and kinase modulators have been identified (16) , the detailed mechanism of the action of calpain, particularly in vivo, has remained elusive. One of the drawbacks to addressing this issue lies in the redundancy of the protease; there are at least two molecular species of ubiquitous calpain, the -calpain and m-calpain isoforms, which require micromolar and millimolar calcium, respectively, for activation in biochemical terms (6, 17) . Each of these isoforms is a heterodimer composed of a distinct 80-kDa catalytic subunit and an identical 30-kDa regulatory subunit. Therefore, the structure of the large subunit determines the biochemical properties of the isoforms. Interestingly both the large and small subunits possess multiple calcium-binding sites (18, 19) , indicating that the two subunits probably interact with each other in a dynamic manner in the presence of calcium. Most researchers familiar with the biochemical properties of these calpain isoforms had presumed that -calpain, which can be activated by submicromolar levels of calcium in the presence of phospholipids (20, 21) , rather than m-calpain, would be the main participant in physiological processes, but this presumption has been entirely upset by findings from studies using reverse genetic approaches.
While genetic deletion of the commonly shared 30-kDa subunit resulted in disappearance of both -and m-calpains leading to embryonic lethality (22) , deletion of the -calpain large subunit apparently led to no severe phenotypes (23) , indicating that m-calpain is likely to play an essential role in early developmental processes. Consistently genetic deficiency of the m-calpain 80-kDa subunit resulted in a lethal phenotype, 1 although it remains possible that -and m-calpains may function in a cooperative manner under certain circumstances. These reverse genetic observations are contradictory to the biochemistry-based analysis of calpain isoform functions as stated above. The mechanism of m-calpain activation in vivo remains unknown but may be associated with cell adhesion because m-calpain was shown to colocalize with adhesion molecules (24) and because calpain has been identified only in multicellular organisms (6) . In any case, this complexity of subunit composition and function of calpain isoforms together with the coexistence of these isoforms in various cell types including neurons (25) makes the reverse genetic approaches targeting calpain subunits less powerful than expected in addressing the pathophysiological roles of calpain in vivo. Another technical problem in calpain research is that there have been no solely calpain-specific synthetic inhibitors; most, if not all, of the synthetic "calpain inhibitors" thus far used inhibit other cysteine proteases represented by cathepsin B as potently as calpain (26) , making it difficult to draw definitive conclusions from experiments using synthetic inhibitors.
To overcome these drawbacks and to gain new insights into the pathophysiological roles of calpain, we focused our attention in the present study on calpastatin. This protein is composed of ϳ700 amino acid residues and has been biochemically characterized as a potent stoichiometric inhibitor of both -calpain and m-calpain in an identical manner (27) . One molecule of calpastatin inhibits four molecules of calpain. The binding affinity of calpastatin to calpain is so high in the presence of calcium that the K i values are extremely low (28) . Calpastatin is the only solely calpain-specific inhibitor that has ever been identified or synthesized to our knowledge. In addition, there is no molecular redundancy unlike the family of caspase inhibitors. Therefore, manipulation of calpastatin expression levels 1 J. Takano and T. C. Saido, unpublished observation.
FIG. 1. Targeting of calpastatin gene.
A, schematic representations of calpastatin cDNA, wild-type calpastatin allele, targeting vector, and targeted allele. Calpastatin is composed of an amino-terminal leading domain (L) and a carboxyl terminus with repeated calpaininhibitory domains I-IV. Each calpain-inhibitory domain comprises regions A and C for binding with calpains and region B for inhibitory action. B, Sp, and Sc indicate the positions of BamHI, SphI, and ScaI restriction endonuclease cleavage sites, respectively. Homologous recombination replaced an SphI-SphI fragment containing the 3Ј end of exon 6 in the calpastatin gene with a cassette composed of three tandem polyadenylation sequences (pA x3) and the neomycin resistance gene driven by the pgk promoter (pgk-Neo). Diphtheria toxin A fragment (DT-A) was used for negative selection. Positions of probes used to genotype the mutants are shown beneath the scheme of the targeted allele. B, Southern blot analysis of progenies from a cross of F1 heterozygote. Genomic DNA was digested with BamHI and blotted on nylon membranes after electrophoresis in 0.7% agarose gels. Ϫ/Ϫ, mutant homozygote; ϩ/Ϫ, heterozygote; ϩ/ϩ, wild type. Membranes were hybridized with 5Ј and 3Ј probes shown in A. The 13-kb band representative of wild-type calpastatin and the 7.5-kb band detected by the 5Ј probe and 9.0-kb band detected by the 3Ј probe of the targeted allele are indicated. C, Northern blot analysis of calpastatin and -calpain. Polyadenylated RNA from cerebral cortex was probed with cDNA encoding calpain-inhibitory domain IV in calpastatin and -calpain domain IV. Full-length ␤-actin was used as an internal control. D, Western blot analysis of calpastatin and m-calpain. Total protein extracts from cerebral cortex were subjected to Western blotting using antibodies against the carboxyl terminus of calpastatin and the amino terminus of m-calpain. E, RT-PCR analysis of calpastatin mRNA. Cortical polyadenylated RNA extracts were subjected to RT-PCR using primers to amplify calpastatin cDNA between exons 4 and 14. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was used as an internal control. F, immunohistochemistry of calpastatin in the hippocampus. The brains from wild-type, heterozygous knock-out, and homozygous knock-out mice (male, 3 months old) were immunostained using an antibody to the carboxyl terminus of calpastatin. G, Western blot analysis using anti-␣II-spectrin antibody. Hippocampal homogenates from wild-type mice treated with and without kainate, untreated heterozygous knock-out mice, and untreated homozygous knock-out mice were subjected to Western blotting using antibodies (clone AA6) to the carboxylterminal portion of ␣II-spectrin. The 240-kDa band, 150-and 145-kDa bands, and 120-kDa band correspond to intact ␣II-spectrin, calpaincleaved fragments, and caspase-cleaved fragment, respectively. "KA" indicates an extract from hippocampal tissue taken 24 h after kainate administration.
in vivo should have profound and specific effects on the proteolytic activity of both calpain isoforms and thus should shed light on the function of ubiquitous calpain as a whole regardless of calpain isoform redundancy, although there is the problem that a calpastatin deficiency might result in a lethal phenotype due to the overactivation of calpain. We therefore adopted two different strategies that involved developing calpastatin-deficient mice and calpastatin-overexpressing mice by reverse genetic methods and analyzed calpain activation and subsequent cellular events evoked by excitotoxicity. Surprisingly and luckily to us, genetic modulation of calpastatin expression levels did not cause any defect in the development, fertility, morphology, or life span of the mice under normal conditions, indicating that calpastatin is a negative regulator of calpain only under pathological conditions. This suggests that calpastatin knock-out and transgenic mice will serve as ideal models to examine whether and how calpain participates in various pathological processes. We also attempted to induce typical caspase-dependent apoptosis in adult mouse brains. Failure to achieve this due to a drastic postdevelopmental reduction of caspase-3 expression in brain tissues will also be discussed.
MATERIALS AND METHODS
Targeting of Calpastatin Gene-A genomic DNA clone of mouse calpastatin was isolated from the 129/Sv mouse strain taken from a bacterial artificial chromosome library as described previously (29) . The targeting vector was generated using the following DNA fragments: a 1.5-kb SphI fragment from intron 4 to exon 6, three tandem repeats of 250-bp SV40 early mRNA polyadenylation signals to terminate transcription (30), a 5.5-kb SphI-ScaI calpastatin gene fragment from intron 6 to intron 8, a 2.0-kb pgk-neo gene cassette (for positive selection), and a 1.0-kb SacI-NotI diphtheria toxin A fragment cassette from pMC1DT-A (for negative selection) (31, 32) . Polyadenylation signals were placed in exon 6 to inhibit transcription of the calpain-inhibitory domains (30) .
E14 cells derived from strain 129/Ola mouse blastocysts were used as an embryonic stem cell line (33) . Cell culture and the targeting experiments were carried out as described previously (34) . In brief, the embryonic stem cells were electroporated with a Gene Pulser (800 V and 3 millifarads with a 0.4-cm electrode distance, Bio-Rad) using 30 g of linearized targeting vector generated by NotI treatment. Clones selected with G418 at 150 g/ml were screened and identified by hybridization with 5Ј and 3Ј external probes following BamHI digestion of genomic DNA (Fig. 1, A and B) . Chimeric mice were generated as described previously by Bradley et al. (35) . Embryonic stem cells were microinjected into C57BL/6J blastocysts at 3.5 days postcoitum. After injection, the embryos were transferred into the uteri of pseudopregnant ICR mice. Mice heterozygous for the mutation were further intercrossed to obtain the chimera to C57BL/6J mice. The genotypes of the mice were determined by Southern blot analysis of genomic DNA prepared from their tails. The heterozygous mice were then backcrossed with C57BL/6 mice five to six times. To obtain homozygotes, the resulting heterozygotes were intercrossed. All mice were maintained by the Research Resource Center, RIKEN Brain Science Institute; all animal experiments were carried out according to the guidelines for animal experimentation in RIKEN.
Calpastatin Transgenic Mice-The human calpastatin cDNA (36) was cloned into pNN265 from which the NotI fragment was subcloned into pMM403 containing the calcium/calmodulin-dependent protein kinase-II ␣ subunit promoter (37) . The SfiI-linearized DNA construct was microinjected into the pronucleus of C57BL/6Cr zygotes, which were transferred into foster females to create calpastatin transgenic founders. The genotype was determined by PCR with specific primers 5Ј-CATGAACCACAGACAGCTTGGTTGAC-3Ј and 5Ј-GGAGGATTT-GATATTCACCTGGCCCG-3Ј that generate a 350-bp product. We confirmed that the transgene-derived human calpastatin was robustly expressed in hippocampus and neocortex. The details of the characterization of the mice are described elsewhere (38) .
Northern Blotting and Reverse Transcription-PCR-Polyadenylated RNA was isolated from half-cortex brain samples using a Micro-Fast Track TM 2.0 kit (Invitrogen). Samples were electrophoresed in 1% formaldehyde agarose gels and transferred to nylon membranes. The membranes were probed with [␣-
32 P]dCTP-labeled fragments of calpastatin and -calpain cDNAs. Specific cDNA probes encoding the inhibitory domain IV of mouse calpastatin and encoding domain IV of mouse -calpain, respectively, were used. The gels were stained with ethidium bromide, and membranes were reprobed with an actin cDNA (Sigma) to confirm the quantity of DNAs loaded.
Reverse transcription (RT) 2 -PCR was carried out using polyadenylated RNA obtained as described above by methods described previously (29) . PCR products were electrophoresed on 5% polyacrylamide gels. Gels were stained with ethidium bromide (1 g/ml), and then DNA fragments were visualized under short wave (254 nm) UV illumination and photographed. For direct sequencing of the short DNA PCR products, DNA fragments were excised from the polyacrylamide gels under long wave (365 nm) UV illumination. Nucleotide sequences were determined with an automated fluorescent sequencer, ABI PRISM 3700 (PerkinElmer Life Sciences), using a BigDye terminator cycle sequencing ready reaction kit (PerkinElmer Life Sciences).
Calpastatin Activity Assay-Cortical tissues (120 mg) from wild-type, calpastatin Ϫ/Ϫ , and calpastatin transgenic mice were homogenized in 2.5 ml of 20 mM Tris-HCl buffer (pH 7.5) containing 5 mM EDTA and 0.1% Triton X-100 at 100°C and then ultracentrifuged at 4°C. The supernatants were subjected to ion-exchange chromatography using a DEAD-Toyopearl 650S (Tosoh) column (0.5 ϫ 5 cm) with a linear gradient (0 -0.5 M) of NaCl and then to calpastatin activity assays using 14 C-labeled casein (100 g; 4200 dpm) and bovine m-calpain (0.45 unit) as described previously (39) . The activity to inhibit the m-calpain activity was defined as calpastatin activity.
Subcellular Fractionation-Hippocampal tissues taken from the brains perfused with ice-cold phosphate-buffered saline (PBS) were homogenized by 20 strokes of a Dounce homogenizer in 10 volumes of 2 The abbreviations used are: RT, reverse transcription; AIF, apoptosis-inducing factor; EndoG, endonuclease G; MAP2, microtubule-associated protein 2; ICAD, inhibitor of caspase-activated DNase; CAD, caspase-activated DNase; PBS, phosphate-buffered saline; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; Tricine, N- [2- 14 C-Labeled casein (4200 dpm) and purified bovine mcalpain (0.45 unit) were used for the calpastatin assays (38) . The bovine m-calpain exhibited an activity of releasing radioactivity of 600 dpm in the absence of calpastatin. B, quantified cortical calpastatin activities from calpastatin Ϫ/Ϫ , wild-type control, and transgenic (Tg) mice. The sums of calpastatin activities from the brains of the mutant mice shown in A were normalized against that of the wild-type control. n.d., not detectable.
ice-cold buffer M (210 mM mannitol, 70 mM sucrose, 10 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1ϫ protease inhibitor mixture, EDTA-free (Roche Applied Science). Homogenates were centrifuged twice at 1500 ϫ g for 5 min at 4°C to remove unlysed cells and nuclei. The supernatants were centrifuged at 10,000 ϫ g for 10 min at 4°C. Pellets were saved as the mitochondrial (high density membrane) fractions. The supernatants were centrifuged at 100,000 ϫ g for 1 h at 4°C and saved as the cytosolic (S100) fractions. The high density membrane fractions were lysed in buffer MX (buffer M with 1% Triton X-100) for immunoblotting. Protein concentrations were assayed with the Micro-BCA protein assay kit (Pierce) using bovine serum albumin as a standard.
Western Blotting-Protein samples denatured in SDS sample buffer (0.25 M Tris-HCl (pH 6.8), 1% SDS, 25% glycerol, 5% 2-mercaptoethanol) were subjected to SDS-PAGE in Tris-Tricine buffer and blotted onto polyvinylidene difluoride membranes. Blotted membranes were blocked with 5% skim milk in PBS containing 0.1% Tween 20 (PBST) for 1 h and then incubated with primary antibodies for 16 h at 4°C.
FIG. 3. Hippocampal neurodegeneration 24 h after kainate administration in mutant mice.
A-D, histochemical analyses of DNA fragmentation and MAP2 degradation. Calpastatin knock-out (Ϫ/Ϫ), wild-type (ϩ/ϩ), and calpastatin-overexpressing transgenic (Tg) mice were sacrificed 24 h after unilateral injection of kainate or PBS as indicated and subjected to histochemistry using TUNEL (A), propidium iodide (B), anti-MAP2 antibody (C), and Cresyl Violet (D). Bars indicate 50 m in A and B and 100 m in C and D. E, quantitative analysis of kainate-induced DNA fragmentation and MAP2 degradation. The images in A-C were quantified as described previously (45) . The left graph shows the percentage of TUNEL-positive neurons among propidium iodide-positive cells in the CA1 sector of the hippocampus. The right graph shows MAP2 immunoreactivity in the same region. Sections from mouse brains, into which PBS was injected, were used as controls. Bars indicate averages Ϯ S.E. (n ϭ 8 or 9). *, p Ͻ 0.05; **, p Ͻ 0.01 (as compared with ϩ/ϩ mice).
After three washes in PBST, the membranes were incubated with anti-mouse or anti-rabbit IgG, horseradish peroxidase-linked F(abЈ) 2 fragment (Amersham Biosciences) for 2 h. Immunoreactive signals were detected with the ECL Advance Western blotting detection kit (Amersham Biosciences) and quantified with a LuminoImager, LAS-3000, and Science Lab 2001 Image Gauge software (Fuji Photo Film) as described previously (40) .
Primary Antibodies-An antipeptidic antibody against the carboxyl terminus of mouse calpastatin was generated using a synthetic peptide, CKKTEEVSKPKAKEDARHS, conjugated to keyhole limpet hemocyanin as described previously (41, 42 ). An antibody specific to the calpain cleavage site of the amino-terminal 135-kDa fragment of ␣II-spectrin was produced according to Manya et al. (43) . Antibodies to m-calpain, inhibitor of caspase-activated DNase (ICAD), and caspase-activated DNase (CAD) were described previously (44, 45) . The following antibodies were purchased as indicated: mouse monoclonal anti-microtubule-associated protein 2 (MAP2) (clone AP20, Leinco Technology), ␣II-spectrin (clone AA6, Biohit), and cytochrome c oxidase subunit I (clone 1D6, Invitrogen) antibodies; a goat polyclonal antibody to caspase-3 (K-17, Santa Cruz Biotechnology); and rabbit polyclonal antibodies to activated caspase-3 (Asp-175, Cell Signaling Technology), endonuclease G (EndoG) (AB3639, Chemicon), apoptosis-inducing factor (AIF) (AB16501, Chemicon), and Bid (AR-52, Alexis).
Intrahippocampal Injection-Stereotaxic administration of kainate into the hippocampus was performed as described previously (46) . Briefly adult male mice were deeply anesthetized with sodium pentobarbital, placed in a stereotaxic apparatus, and given a unilateral injection of 0 or 0.1 nmol of kainate in 0.3 l of PBS into the hippocampal CA1 region using a 26S-gauge needle equipped with a 0.5-l motorized syringe (Hamilton). The coordinates of the injection were anterior-posterior Ϫ2.3 mm, medial-lateral Ϫ1.5 mm, and dorsal-ventral Ϫ1.6 mm from the bregma. Two minutes after the needle insertion, kainate was injected at a constant flow rate of 0.05 l/min. The needle remained in place for an additional 2 min to prevent reflux of fluid.
Histochemistry-Twenty-four hours after injection of kainate or PBS, mice were anesthetized with sodium pentobarbital (50 mg/kg of body weight) and perfused through the heart with ice-cold PBS followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed, postfixed in the same fixative overnight at 4°C, and embedded in paraffin. Coronal sections (4 m thick) were then dehydrated and stained with 1% Cresyl Violet to confirm the injection site. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) was carried out using an in situ cell death detection kit (Roche Applied Science) according to the manufacturer's instruction. For quantification of cell death, we counted the number of TUNELpositive cells and propidium iodide-stained nuclei in hippocampus. The immunohistochemical analysis was performed with the tyramide signal amplification method using a tyramide signal amplification fluorescence system (PerkinElmer Life Sciences) as described previously (40) . Quantification of immunoreactivity was carried out using MetaMorph (version 6.1) imaging software (Universal Imaging Corp.) as described by Iwata et al. (40, 47) .
Statistical Analysis-The statistical significance was examined by Student's t test after confirming the equality between the group variances or by Fisher's protected least significant difference when it was necessary. A probability level of p Ͻ 0.05 was accepted as statistically significant in all of the studies.
RESULTS
Fig . 1A summarizes the strategy used to generate calpastatin knock-out mice. The targeting vector carrying three tandem polyadenylation sequences was inserted into exon 6 to terminate transcription through homologous recombination (30) for the following reasons. (i) Every exon is composed of 3ϫ multiple numbers of base pairs, making a frameshift strategy inadequate (29) . (ii) The calpastatin gene possesses multiple sites for initiation and termination of transcription (48) . (iii) A neighboring adipocyte-derived leucine aminopeptidase gene overlaps with part of the calpastatin gene corresponding to the fourth inhibitory domain (49) . (iv) The gene region encoding calpaininhibitory domains starts at exon 9 (29) . Southern blot analyses of BamHI-digested genomic DNA using 5Ј and 3Ј probes designated in Fig. 1A indicate that the gene targeting was successfully achieved as intended (Fig. 1B) . We then performed Northern blotting, Western blotting, RT-PCR, and immunohistochemistry to confirm the amounts of calpastatin gene products in heterozygous (ϩ/Ϫ) and homozygous (Ϫ/Ϫ) mice as compared with wild-type mice (ϩ/ϩ) (Fig. 1, C-F) . The amount of calpastatin mRNA and corresponding anti-calpastatin antibody-immunoreactive protein decreased in a gene dose-dependent manner, whereas the levels of -calpain, m-calpain, and ␣II-spectrin (fodrin) remained unchanged (Fig. 1, C and D) .
Calpastatin appeared as doublet bands in Western blotting due to the presence of distinct initiation sites for transcription in the calpastatin gene (50) . Interestingly a trace amount of anti-calpastatin antibody immunoreactivity with lower molecular weight was detected in knock-out mice (Fig. 1D) . This is likely to have resulted from the skipping of exon 6, into which polyadenylated signals were inserted (see Fig. 1A ), during splicing because RT-PCR using primers spanning exons 4 and 14 indicated the presence of a calpastatin transcript ϳ120 bp smaller in the knock-out mouse brain (Fig. 1E) . This assumption was confirmed by sequencing the PCR product. Therefore, the present gene targeting strategy did not achieve 100% deletion of calpastatin gene expression in the strictest sense, but the amount of the remaining calpastatin is negligibly small in the homozygous knock-out mice as indicated by immunohistochemistry (Fig. 1F) . Incidentally there was no detectable calpain activation in the calpastatin Ϫ/Ϫ mouse brain under normal conditions (Fig. 1G) . Calpastatin activity assays following the standard procedures to biochemically fractionate calpastatin by ion-exchange column chromatography indicated that the calpastatin activity was reduced to an undetectable level in the calpastatin Ϫ/Ϫ mouse brain, while the calpastatin activity was 3 times larger in the calpastatin transgenic mice than in the wild-type controls (Fig. 2) . Because calpastatin is proteolytically degraded after calpain activation (51-53), a reduction of calpastatin activity by nearly 100% is practically equivalent to making calpain free from inhibition of the enzymatic activity.
FIG. 4. Expression and activation of caspase-3 and proteolysis of ICAD in mouse brains.
A, expression of caspase-3 in the brain at postnatal day 1 (P1) and 12 weeks after birth (12w). Soluble fractions of brain homogenates from postnatal day 1 and 12-week-old mice were subjected to Western blotting using an anti-caspase-3 antibody. B, caspase-3 activation in the postnatal day 1 brain and kainate-treated adult hippocampus. Sections from postnatal day 1 brain and kainatetreated adult hippocampus were immunostained using an activated caspase-3-specific antibody and counterstained with propidium iodide as indicated. The bar indicates 25 m. C, effect of kainate treatment on ICAD in calpastatin knock-out mice and normal controls. Hippocampal homogenates were subjected to Western blot analysis using an antibody to ICAD. ICAD-L, long form of ICAD; ICAD-S, short form of ICAD (56) . KA, kainate.
Thus, the calpastatin Ϫ/Ϫ mice generated here can be considered as calpastatin knock-out mice rather than knock-down mice.
Despite our initial reservations (see the Introduction), calpastatin Ϫ/Ϫ mice showed normal development, fertility, morphology, and life span as compared with calpastatin ϩ/ϩ mice under normal physiological conditions, suggesting that calpastatin is a negative regulator of calpain only under pathological conditions. Consistently there was no evidence of calpain activation in calpastatin
, or calpastatin ϩ/ϩ mice under normal conditions as determined by the limited proteolysis of ␣II-spectrin, a substrate highly sensitive to calpain (Fig. 1G) . In contrast, kainate-induced calpain activation was augmented in calpastatin Ϫ/Ϫ mice (see later sections). It is also noteworthy that there was no detectable spectrin fragment (120 kDa) generated by caspase (54) in the kainate-treated hippocampus in the present experimental paradigm (Fig. 1G, first lane) . There was no difference between calpastatin Ϫ/Ϫ and calpastatin ϩ/ϩ mice in the immunohistochemical quantities and distributions in calpain-proteolyzed spectrin, NeuN, MAP2, tau, Cdk5-phosphorylated tau (AT-8 antigen), synaptophysin, synaptobrevin, syntaxin, SNAP25 (synaptosomal-associated protein of 45 kDa), GAP43 (growth-associated protein 43), glutamic acid decarboxylase 65, vesicular ␥-aminobutyric acid transporter, or glutamate receptor 1 under normal conditions either (data not shown). Although it is possible that a trace amount of remaining calpastatin generated by exon skipping may contribute to the regulation of physiological calpain activities, this assumption is unlikely because there was no statistical difference between calpastatin ϩ/ϩ and calpastatin Ϫ/Ϫ mice even in terms of life span of mice, which encompasses the summation of development, maturation, and aging together.
We then examined the effect of kainate (0.1 nmol), which was injected stereotaxically into the CA1 sector of the hippocampus in calpastatin Ϫ/Ϫ mice, wild-type controls, and calcium/calmod- ulin-dependent protein kinase-II ␣ subunit promoter-driven transgenic mice overexpressing calpastatin (Fig. 3) . TUNEL and counter staining of nuclei using propidium iodide indicated that calpastatin deficiency resulted in augmented DNA fragmentation 24 h after the excitotoxic treatment of CA1 pyramidal neurons. Calpastatin overexpression suppressed the appearance of lesions (Fig. 3, A and B) . Consistently degradation of MAP2, another substrate sensitive to calpain, was augmented and suppressed in calpastatin-deficient and calpastatin-overexpressing mice, respectively (Fig. 3C) . Apoptotic morphological changes represented by the shrinkage of nuclei and soma in Cresyl Violet-stained pyramidal neurons (Fig. 3D ) were also consistent with the above observations. Quantitative image analyses of these data indicate that DNA fragmentation as well as MAP2 degradation was augmented by calpastatin deficiency. Consistently calpastatin overexpression suppressed these responses in a statistically significant manner (Fig. 3E) .
Because calpastatin inhibits calpain in a specific manner, these observations strongly suggest that calpain activation is exclusively involved in the DNA fragmentation and morphological changes of neurons displaying typical features of apoptosis.
No evidence of caspase activation, which would have led to the generation of the 120-kDa fragment of ␣II-spectrin (54), was detected in the present experimental paradigm (Fig. 1G) , thus indicating that calpain activation leads to caspase-independent neuronal cell death (see also the following sections). When a higher dose of kainate (1 nmol) was injected into the hippocampus, we were able to detect a subtle but distinct caspase activation, indicated by fractin (caspase-cleaved actin) immunoreactivity (55) , in the CA3 sector, but transgenic expression of baculoviral caspase inhibitor p35 had no effect on DNA fragmentation, whereas the caspase activation was fully inhibited (46) . To further examine this finding, we observed expression and activation of caspase-3, a central downstream "executioner" caspase, in neonatal and adult brains (Fig. 4) . While expression of calpain was similar between neonatal and adult brains (data not shown), that of caspase-3 was much lower in adult brains compared with neonatal brains (Fig. 4A) . Consistently immunohistochemistry using an antibody specific to activated caspase-3 indicated that caspase-3 was clearly activated during early development of the brain, whereas there was no detectable caspase-3 activation following kainate treatment in the adult brain under the present experimental paradigm (Fig.  4B) . The anti-fractin antibody originally described by Yang et al. (55) also did not detect any immunoreactive signal (data not shown). These observations are consistent with a previous report by Shimohama et al. (56) demonstrating that cortical caspase-3 and caspase-7, which are highly expressed in the embryonic stage and up to 2 weeks postnatally, become virtually undetectable from 4 to 96 weeks after birth in rat brains.
Since caspase-3 is not activated, the CAD/ICAD system (57, 58) is unlikely to be involved in calpain-mediated DNA fragmentation. Indeed there was no kainate-induced degradation of ICAD identified even in calpastatin Ϫ/Ϫ mice (Fig. 4C ). An anti-CAD immunoreactivity was below the detection limit in immunohistochemistry. We therefore investigated possible participation of other major DNA fragmentation factors (59, 60) . We found that a mitochondria-derived proapoptotic factor, AIF (61), translocated into nuclei and that this translocation was augmented by calpastatin deficiency; calpastatin overexpression suppressed this response (Fig. 5). In addition, Fig. 6 shows that a mitochondria-derived DNase, EndoG (62), also translocated into nuclei following kainate administration and that the extent of translocation was again augmented by calpastatin deficiency; calpastatin overexpression suppressed this response again. AIF has been shown to cause DNA fragmentation and chromatin condensation possibly in a cooperative manner with EndoG (62, 63) . These observations are consistent with previous reports (64, 65) showing that focal cerebral ischemia induces nuclear translocation of AIF and that EndoG is involved in neuronal excitotoxicity using EndoG-deficient mice. The question then is how calpain activation leads to nuclear translocation of these mitochondria-derived DNA fragmentation factors.
We confirmed that calpain activation was enhanced in calpastatin Ϫ/Ϫ mice in an earlier stage of the excitotoxic processes, i.e. 4 h after kainate administration, by using an antibody specific to the calpain-cleaved amino-terminal 135-kDa fragment of ␣II-spectrin (43) (Fig. 7A) . The enhancement of calpain-catalyzed spectrin fragmentation was statistically significant (Fig. 7B ). This observation was further confirmed using another antibody (AA6) that recognizes a different epitope in the carboxyl-terminal region of ␣II-spectrin as indicated by increased immunoreactive bands of 150 and 145 kDa. In contrast, there was no difference in the appearance of the 120-kDa fragment that would have been generated if caspases had been activated (54) .
We then analyzed possible cleavage of a proapoptotic Bcl-2 subfamily member, Bid (66), because Bid can be proteolyzed by the action of calpain (67) and because truncated Bid, tBid, has been shown to cause disintegration of mitochondria in vitro (68, 69) . As shown in Fig. 6 , kainate-induced generation of tBid, which translocated from cytosolic fractions to mitochondria fractions, was significantly increased in calpastatin Ϫ/Ϫ mice. Translocation of AIF appears to precede that of EndoG because AIF, but not EndoG, fully colocalized with nuclei 12 h after kainate administration (Fig. 8) . AIF translocated to nuclei only partially 4 h after kainate treatment (data not shown). These results indicate that, prior to mobilization of AIF and EndoG, calpain cleaved Bid and that tBid then translocated to mitochondria and induced mitochondrial membrane permeabilization and the release of these DNA fragmentation factors resulting in neurodegeneration as summarized in Fig. 9 . There remains a possibility, however, that calpain may have acted on other unidentified protein(s) and that fragment(s) generated FIG. 7 . Examination of early calpain and caspase substrate proteolysis prior to DNA fragmentation. A, immunoblot analysis of ␣II-spectrin and Bid. Hippocampal lysates from mouse brains 4 h after administration of kainate or PBS were homogenized and then fractionated to mitochondrial (high density membrane (HM)) and cytosolic (S100) fractions. The whole homogenates were analyzed by Western blotting using an antibody specific to the calpain-cleaved amino-terminal fragment of ␣II-spectrin and another antibody (clone AA6) to the carboxyl-terminal region of ␣II-spectrin. High density membrane and S100 fractions were subjected to Western blotting using an antibody against full-length Bid. Full-length Bid (21 kDa) was converted by calpain-dependent proteolysis to tBid (13 kDa), which translocated to mitochondria. B, quantitative analysis of calpain-cleaved spectrin in the whole homogenates and truncated Bid in the mitochondrial fractions. Western blot data were densitometrically quantified and normalized to data from kainate-treated wild-type (ϩ/ϩ) mice. Bars indicate averages Ϯ S.E. (n ϭ 4 -6). *, p Ͻ 0.05 as compared with ϩ/ϩ mice. KA, kainate. could also participate in permeabilization of mitochondria. It is also possible that DNases other than AIF and EndoG may participate in the calpain-mediated DNA fragmentation.
DISCUSSION
In the realm of neurodegeneration research, there has been a rather rigid belief that caspases function as a predominant executioner of cell death (70 -72) . This is conceivably due to the fact that most cell biological studies on the mechanism of neurodegenerative processes have used primary neurons prepared from embryonic brains (73) , which express a robust amount of caspase-3, the executioner in the final stage of the caspase-dependent apoptotic cascade. In contrast, adult brains express a negligibly small amount of caspase-3 (Fig. 4) . Therefore, neurodegeneration-associated studies using primary neurons provide only a limited amount of information for understanding the pathological processes that take place in adult brains. Indeed, whereas caspase-dependent apoptosis is readily detectable during development in vivo or in cultured cells in vitro, very few studies, if any, have clearly demonstrated that typical and strictly defined caspase-dependent apoptotic processes arise in adult brains. We have made a number of efforts to induce such apoptotic lesions in adult brains by stereotaxically injecting various "apoptosis-inducing reagents" such as ionomycin, staurosporine, tunicamycin, amyloid ␤ peptide, proteosome inhibitors, and endoplasmic reticulum stress inducers, but none of them evoked typical apoptosis accompanying caspase-3 activation (46). 3 Although it remains possible that other caspase family members known to be present in the adult brain or a trace amount of caspase-3 may have been activated, the lack of ICAD fragmentation, at least, in the present experimental paradigm indicates that the caspase cascade, which could be initiated by the release of mitochondrial cytochrome c that activates caspase-9 together with Apaf-1 (74), did not result in mobilization of executioner caspase(s), the substrate specificity of which should resemble that of caspase-3. We would like to emphasize again that examination of neurotoxicity using primary neurons, still used even in the latest highly evaluated studies (75) , provides little, if any, information regarding the mechanism of neurodegenerative processes that generally develop in adult brains. This precaution may apply to cell death processes in some other tissues as well.
Consistently the concept of caspase-independent apoptosis is emerging as a possible mechanism that may account for cell death under various pathological conditions (59, 60, 76) , although to our knowledge no mechanistic cause-and-effect relationship, particularly in vivo, has been established in a unified and integrated manner. We demonstrated previously that transgenic overexpression of viral caspase inhibitor p35 suppresses higher dose (0.5-1 nmol) kainate-induced caspase activation detected as fractin immunoreactivity but does not influence neurodegeneration (46) . In contrast, calpastatin overexpression clearly inhibited both calpain-dependent proteolysis of cytoskeletal proteins and subacute neurodegeneration (38) . These observations led us to speculate that proteolytic disorganization of cytoskeletal structures by calpain may contribute to the morphological degeneration of neurons. Alteration of the phosphorylation status of cellular proteins such as tau through calpain-catalyzed limited proteolysis of Cdk5 modulator, p35 (10, 77) , protein kinase C family members (78), etc. is also likely to be involved possibly in a synergistic manner. These assumptions, however, do not fully account for the mechanism by which apoptotic DNA fragmentation is evoked in the nuclei of neurons. In the present study, we used a lower dosage (0.1 nmol) of kainate, which induces moderate lesions similar to those caused by transient forebrain ischemia, an experimental model of clinical ischemic conditions that can be caused by various insults such as strokes, vasospasm, and cardiac infarction (79, 80) . The present results strongly suggest that calpain plays a central role in the excitotoxic signal transduction cascade leading to DNA fragmentation. This cascade is likely to be triggered by calpain-dependent activation of mitochondria-permeabilizing molecule(s) represented by Bid, which induces nuclear translocation of the proapoptotic factors, such as EndoG and AIF, from the mitochondria (Fig. 9) .
Our results also imply that calpain is likely be directly involved in other neuronal disorders that are accompanied by abnormal calcium homeostasis in neurons (7, 9, 11, 13) . If so, the presence of calpastatin will decelerate the neurodegenerative processes in a quantitative manner. The best approach to examine this possibility is to expose calpastatin knock-out mice, which remain normal under physiological conditions, to the pathological conditions. This could be done by crossbreeding the mice with mouse models of given diseases. In this manner, different pathological conditions can be analyzed in two ways: one that involves calpain activation (Fig. 9) and the other that proceeds in a calpain-independent manner. For the first category of diseases, inhibitors that are strictly calpainspecific could be chemically synthesized and used to medically treat the condition. These inhibitors would act on the activated form of calpain to alleviate patients' symptoms without causing adverse side effects, given that in the mouse model modulation of the expression levels of calpastatin does not seem to result in any abnormality in mice under normal conditions. Acknowledgments-We thank M. Sekiguchi, N. Yamazaki, and Y. Onodera for technical assistance. We are also grateful to S. Nagata for providing the anti-ICAD and anti-CAD antibodies and to M. Hooper for providing the embryonic stem cell line. 3 M. Tomioka and T. C. Saido, unpublished observations. FIG. 9. Schematic representation of the mechanism of calpainmediated excitotoxicity leading to neuronal DNA fragmentation in the adult brain. Our results indicate that excitotoxicityinduced DNA fragmentation in the adult brain (hippocampus) was triggered by calpain-dependent proteolytic activation of a mitochondriapermeabilizing molecule represented by Bid, which induces nuclear translocation of the proapoptotic factors, AIF and EndoG, from mitochondria. AIF and EndoG cause chromatin condensation and DNA fragmentation in a cooperative manner. There remains a possibility that unidentified mitochondria-permeabilizing protein(s) other than Bid may be proteolytically activated by calpain. It is also possible that DNases other than AIF and EndoG may participate in the calpainmediated DNA fragmentation. Because caspase-3 was undetectable and given that no fragmentation of ICAD was observed, involvement of the caspase cascade in the apoptotic processes described here is unlikely. CytoC, cytochrome c; Casp3, caspase-3.
